Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy (NCT02966314), a randomized phase 4 study. The primary outcome is Mean 7-day Angioedema Activity Score (AAS7).

2. Clinical Question

The clinical question concerns a condition described in the registry summary as idiopathic angioedema, including episodes that may be serious when they affect respiratory-tract tissues. The summary also notes that there are no clear management guidelines for clinicians and describes current approaches as including trigger avoidance and medications for prevention or acute events. Those statements provide context for the trial question; they are not results of the randomized comparison.

The trial was exploratory and evaluated omalizumab as add-on therapy in people who remained symptomatic despite current therapy. Its primary outcome was an activity score based on the frequency and intensity of angioedema episodes over 7 days. The question is therefore about measured symptom activity over the treatment period, not about every possible consequence of the condition or a broad assessment of all treatment effects.

The registry record gives no single primary-effect estimate, confidence interval, or p-value. It also indicates that the primary outcome had several categories or time points and was not reduced to one comparison. Consequently, the clinical question can be described from the design and endpoint definition, but the posted information does not support a conclusion about the direction or size of the primary outcome difference.

3. Trial Design

The registry identifies this as a phase IV, randomized, double-blind, placebo-controlled exploratory study with a parallel-group model. It compares omalizumab with placebo in people with idiopathic angioedema who remained symptomatic despite current therapy. Randomization is intended, in general, to make treatment groups comparable on average at the time of allocation; it does not guarantee that groups will be identical, particularly when the enrollment is limited.

The registry lists enrollment of 12. The record does not report the number randomized to each arm in the trial-design details, nor does it state how many participants completed treatment or contributed to each outcome analysis. The safety results separately list five participants at risk in each arm. These safety denominators should be read as the denominators attached to those adverse-event figures, not as a complete account of participant flow.

Double blinding means that the study is described as masking participants and at least one other party involved in the trial, but the registry record does not specify who was masked or how masking was maintained. In general, masking can reduce the risk that expectations affect reporting or assessment. It cannot remove every possible source of bias, and the record does not report a formal assessment of whether masking was successful.

The intervention descriptions identify subcutaneous injections for both omalizumab and placebo. The available omalizumab description is incomplete, so the full administration schedule and other treatment details are not reported in the registry record. The placebo description names sodium chloride 0.9%. The registry lists the sponsor as University of Wisconsin, Madison, and gives a start date of 2017-03-30, a primary completion date of 2020-01-06, and completed status.

The registry lists 12 outcome measures and four analyses. It also indicates that the primary outcome has several categories or time points and is not reduced to one comparison. Thus, the design is identifiable, but the specific analytic contrast needed to interpret a single primary treatment estimate is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Two participants were screened and enrolled but not randomized to an arm to start the study.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Two participants enrolled onto the study were screened but not randomized to an arm.

6. Primary Endpoint

The registry lists the primary outcome as Mean 7-day Angioedema Activity Score (AAS7), measured over baseline to end of treatment period at 6 months.

The primary endpoint is the mean 7-day Angioedema Activity Score (AAS7), described as measuring the frequency and intensity of angioedema episodes. The registry says the score has a total possible range of 0-15 over 7 days, expressed as a mean day sum score, with higher scores indicating increased angioedema activity. The specified timeframe is baseline to the end of the treatment period at 6 months.

As a general statistical concept, a symptom-activity score can summarize several aspects of a condition in a consistent measure. Repeated assessment over a fixed period can make it possible to compare activity across visits or between randomized groups, provided the analysis defines how repeated scores are combined and how missing visits are handled. Those details are not reported in the registry record.

The endpoint’s interpretation depends on both its scale and the comparison being made. A score level describes activity on the measure; a change from baseline describes within-participant change; and a difference in change between groups describes a treatment contrast. These quantities are not interchangeable. The registry gives the endpoint definition and timeframe, but no single primary comparison or numerical estimate is reported, so the magnitude and precision of a group difference cannot be described from the record information available.

The endpoint does not, by itself, describe every aspect of idiopathic angioedema. The record lists secondary outcomes that address quality of life, a visual analog scale, episodes, duration, and urgent-care or emergency-room visits. These are distinct measures and should not be treated as replacements for the stated primary endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods determine how trial observations are turned into estimates and how much uncertainty should accompany those estimates. The registry identifies randomization, double blinding, a parallel-group design, a primary endpoint, and the existence of four analyses. It does not report enough analytic detail to reconstruct the primary comparison or its statistical methods. The explanations below describe general concepts, not methods confirmed for this trial.

What does randomization contribute?

In general, randomization assigns participants to treatment groups using a chance-based process. Its purpose is to reduce systematic differences between groups at the start of the comparison, including differences in measured and unmeasured characteristics. With limited enrollment, random allocation can still leave noticeable imbalances by chance. Randomization does not ensure that all participants provide outcome data, that the analysis preserves the original assignments, or that the outcome is measured without error.

The registry identifies the study as randomized but does not report the randomization sequence method, allocation concealment procedure, or allocation ratio. It also does not state which analysis population was used. These details matter because they help establish whether assignment was protected from influence and whether the analysis followed the randomized comparison.

What does double blinding mean?

In general, blinding is intended to limit the influence of knowledge about treatment assignment on participants’ reports, clinicians’ decisions, outcome assessment, and analysis. The registry describes the trial as double-blind, but does not specify which two parties were masked or the practical procedures used. It does not report whether investigators assessed the success of masking. The label alone therefore describes the stated design, not the degree to which expectations could have influenced particular measurements.

How should a mean endpoint be interpreted?

The AAS7 is described as a mean score over a 7-day period, with higher values indicating increased activity. A mean can summarize observations across participants or days, but its precise interpretation depends on how the score is constructed, which observations enter the calculation, and how incomplete observations are treated. The registry gives the possible score range and direction but does not provide a detailed scoring algorithm or missing-item rule.

For a randomized comparison, an analysis could estimate an end-of-treatment group difference, a change from baseline within each group, or a difference between groups in change. These answer different questions. A within-group change does not by itself establish a treatment contrast, because change can occur in both groups. The registry record does not report which specific contrast was used for the primary endpoint, and the primary outcome is not reduced to one comparison.

What do confidence intervals and p-values convey?

In general, a confidence interval gives a range of values compatible with the observed data under the assumptions of the method. It communicates uncertainty about an estimate and is often more informative than a significance label alone. A p-value describes how compatible the observed data are with a specified null model, subject to the analysis assumptions; it is not the probability that the null hypothesis is true and does not measure the size or clinical importance of an effect.

No primary confidence interval, p-value, or single numerical comparison is reported in the registry record. Therefore, the precision of a primary estimate cannot be assessed. A statistical interpretation would need the estimate, its uncertainty interval, the analysis definition, and relevant assumptions. None should be inferred from the endpoint name or design label alone.

Why can over-dispersion matter?

General explanation: for count outcomes, a simple statistical model may assume that the variability is governed by the mean. Over-dispersion occurs when the observed variability is greater than that assumption allows. If it is ignored, standard errors may be too small and confidence intervals may be too narrow, making evidence appear more precise than it is. Models designed for over-dispersed counts can account for extra variability. The registry lists outcomes involving episodes and events, but does not report whether count models were used or whether over-dispersion was assessed.

What is multiplicity?

General explanation: testing several outcomes, time points, subgroups, or contrasts creates multiple opportunities to observe a result that appears statistically notable by chance. Statistical approaches can control or describe this multiplicity, but their appropriateness depends on the analysis plan and the role of each outcome. The registry lists 12 outcome measures and four analyses. It does not report whether a multiplicity adjustment was planned or applied, how outcomes were prioritized beyond the primary designation, or whether analyses were exploratory or confirmatory apart from describing the study as exploratory.

How should planning illustrations be distinguished from trial results?

General explanation: a sample-size calculation is a planning exercise based on assumptions about the target effect, variability, allocation, and error rates. It is not an observed result and does not show the probability that a particular trial has produced a true finding. The registry material describes a planning-illustration approach based on a fraction of an observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation. It distinguishes participants per arm for most outcomes from total events for time-to-event outcomes. No actual illustration values are included in the record information used here, and the calculation is not the trial’s own design justification. The trial’s sample-size justification is not reported in the registry record.

The record does not report the primary analysis model, covariate adjustment, handling of repeated measurements, assumptions about the score distribution, treatment of outliers, or sensitivity analyses. These omissions prevent a methods-based reconstruction of the primary result, even apart from the absence of a single reported comparison. General statistical principles can explain what such choices do, but cannot establish which choices were made for this trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 12 outcome measures and four analyses. The primary outcome is described as having several categories or time points and not being reduced to one comparison. This means the available information does not identify a single primary contrast with an estimate that can be interpreted as the main treatment effect. The registry record does not report how the multiple outcome measures, time points, or analyses were prioritized or whether any adjustment for multiple testing was used.

In general, multiplicity matters because repeated statistical tests increase the chance of finding at least one apparently unusual result even when no underlying effect exists. The appropriate response depends on whether analyses are confirmatory or exploratory, which outcomes were prespecified, and what family of comparisons is being considered. The trial is described as exploratory, but the detailed analysis plan and multiplicity approach are not reported in the registry record. No statistical significance claim should be inferred without knowing the relevant comparison and its testing context.

Missing-data handling is also not reported in the registry record. The available description does not state how absent visits, incomplete AAS7 observations, withdrawal, or other missing outcome data were handled. In general, missingness can affect both the composition of the analyzed group and the interpretation of an estimate. Methods may rely on assumptions about why data are missing; those assumptions should be stated and examined where appropriate. The record does not identify such assumptions or sensitivity analyses.

The analysis populations are not reported in the registry record. It is therefore unclear whether the primary analysis included everyone randomized, only participants with available measurements, or another defined population. The enrollment count and the safety denominators do not establish the analysis population for the primary outcome. Participant flow by group, exclusions from analyses, and reasons for missing observations are not reported in the record information.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The posted safety figures list five participants at risk in the placebo group and five in the omalizumab group. Serious adverse events are listed as affecting zero participants in each group, and deaths are listed as zero in each group. Other adverse events are listed as affecting zero participants in the placebo group and one participant in the omalizumab group.

These are participant counts, not a complete description of event severity, timing, recurrence, or relationship to study treatment. The record does not list any top serious adverse-event terms. It also does not provide details of the other adverse event affecting one participant, so its nature and clinical significance are not reported in the registry record.

In general, zero events recorded in a limited group do not establish that an event cannot occur, and a difference in small counts does not by itself establish a causal safety difference. A comparative interpretation would require more detail about event definitions, follow-up, exposure, ascertainment, and uncertainty. The registry lists 12 participants enrolled overall, while the safety figures list five at risk in each group; the record information does not explain this denominator relationship. The figures should therefore be read as the posted safety counts, without assuming they account for every enrolled participant.

12. What the Result Does, and Does Not, Mean

The registry record establishes that the study was a randomized, double-blind, placebo-controlled exploratory trial of omalizumab for idiopathic angioedema, with a parallel-group design and enrollment of 12. It defines the primary outcome as mean AAS7 from baseline to the end of the 6-month treatment period. These details allow readers to understand the intended comparison and what the primary measure represents.

The record does not establish a single numerical result for that primary comparison. It states that the primary outcome has several categories or time points and was not reduced to one comparison. No primary estimate, confidence interval, or p-value is reported in the information. That gap means the effect’s direction, size, and precision cannot be described. It does not imply that the groups were equal, and it is not evidence that either treatment was better or worse.

The safety counts describe the listed adverse-event experience in the recorded groups: no serious adverse events or deaths are listed in either group, and one participant in the omalizumab group is listed as having an other adverse event. These counts do not establish comparative safety, particularly without event details, fuller participant flow, and an uncertainty analysis.

The registry lists additional outcomes related to quality of life, visual analog scales, episodes, episode duration, and urgent-care or emergency-room visits. Their presence indicates a broader set of measurements, but the results and analysis details for those outcomes are not reported in the registry information. They cannot be used to fill the gap in the primary comparison.

The appropriate conclusion is limited: the design and endpoint are described, and a small set of safety counts is posted, but the primary treatment contrast cannot be interpreted from the information available. A treatment conclusion would require a clearly specified comparison and its result, together with enough methodological detail to assess uncertainty and possible bias.

13. Why This Trial Matters Statistically

This trial illustrates an important distinction between knowing what a study set out to measure and knowing what its results mean. The registry identifies the clinical population, randomized comparison, masking, endpoint, and treatment timeframe. Those details are essential for framing a statistical question, but they do not substitute for a reported estimate and its uncertainty.

The primary endpoint is a repeated symptom-activity measure, while the registry also lists outcomes concerning quality of life, visual analog scales, episode counts, duration, and urgent-care or emergency-room visits. Each outcome can address a different aspect of the condition. Statistical interpretation depends on knowing which measure is primary, which contrast is being estimated, and how the other analyses are treated. The record lists 12 outcome measures and four analyses but does not report a detailed plan for interpreting them together.

The enrollment listed is 12, and the safety figures list five participants at risk in each group. These counts make clear why estimates and their uncertainty matter: a count alone cannot establish the precision of a treatment comparison. In general, smaller datasets can leave substantial uncertainty, but the actual precision must be judged from an estimate and interval. The primary comparison and its interval are not reported in the registry record.

The trial is described as exploratory. That context matters because exploratory analyses can help characterize questions for further study, but they should not automatically be treated as definitive evidence. The record does not report a sample-size justification, a detailed statistical plan, or a multiplicity approach. A careful statistical reading therefore separates the transparent design details from conclusions that require unavailable results and methods.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting the trial is that the registry information does not report one primary outcome comparison. Although the AAS7, its direction, possible range, and treatment timeframe are described, there is no single estimate, confidence interval, or p-value to assess. The record explicitly indicates that the primary outcome has several categories or time points and is not reduced to one comparison.

The registry lists enrollment of 12, while the safety counts list five participants at risk in each arm. It does not explain the relationship between enrollment and those denominators, report participant flow, or state the number contributing to each efficacy analysis. Completion, withdrawals, exclusions, and reasons for missing observations are not reported in the registry record.

The statistical analysis plan is not reported in the registry record. In particular, the available information does not specify the primary contrast, model, handling of repeated measures, covariate adjustment, missing-data assumptions, analysis populations, or sensitivity analyses. A sample-size justification is also not reported. These absences limit assessment of whether the analysis matched the planned question and how robust any result would be.

The trial is described as exploratory and includes 12 outcome measures and four analyses. The record does not explain the hierarchy among secondary outcomes or whether any method addressed multiple testing. The listed safety counts are also sparse, and the available record does not identify the other adverse event affecting one participant or provide event-level details.

These limitations describe what is absent from the registry information; they do not establish that the study procedures or analyses were inadequate. They do mean that the posted material cannot support a complete evaluation of the primary treatment effect, its precision, or the broader balance of outcomes.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy — NCT02966314.
• Registry record last updated 2022-11-01; status last verified 2022-10.
• Results first posted 2021-11-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed phase IV, randomized, double-blind, placebo-controlled exploratory study of omalizumab for idiopathic angioedema in people who remained symptomatic despite current therapy. The study used a parallel-group design and lists enrollment of 12. Its primary outcome was mean 7-day Angioedema Activity Score (AAS7), measured from baseline to the end of the 6-month treatment period. Higher AAS7 scores indicate increased angioedema activity.

The record lists 12 outcome measures and four analyses. It does not reduce the primary outcome to one comparison, and a primary estimate with its uncertainty is not reported in the information. Safety figures list five participants at risk in each group, zero serious adverse events and zero deaths in both groups, and other adverse events affecting zero participants in the placebo group and one in the omalizumab group.

The statistical analysis plan, missing-data methods, analysis populations, and sample-size justification are not reported in the registry record. The available information therefore describes the study framework and selected safety counts but does not support a numerical interpretation of the primary treatment contrast.